Fusion protein nano vaccine based on RAS variant neoantigen epitopes and preparation method thereof
A fusion protein and antigen epitope technology, applied in the direction of fusion polypeptide, cancer antigen components, chemical instruments and methods, etc., can solve the problems of antigen dispersion, unfavorable immune system recognition and activation, etc.
- Summary
- Abstract
- Description
- Claims
- Application Information
AI Technical Summary
Problems solved by technology
Method used
Image
Examples
Embodiment Construction
[0020] 1) Mutated epitope sequence
[0021] In recent years, with the popularization of gene sequencing, many gene variations that affect the occurrence and development of pancreatic cancer have been identified. The 21kD guanine nucleotide-binding protein RAS (p21RAS) encoded by the human proto-oncogene family is an important member of the cell growth signaling chain. In tumor cells, a single amino acid substitution occurs at position 12 or 13 due to a single nucleic acid mutation in the RAS gene. This mutation leaves RAS in a state of constant signaling activation, which leads to uncontrolled cell growth and cancerous transformation.
[0022] Studies have shown that multiple RAS mutations may be present in the same neoplastic pancreas. Although in pancreatic cancer, RAS mutations mainly occur at position 12, there are also some degree of mutations at positions 13 and 61. These variant antigens represent more than 99% of mutations in RAS proteins in common pancreatic cancer...
PUM
Login to View More Abstract
Description
Claims
Application Information
Login to View More 


